← All organizations

Flamel Technologies

For profit

Also known as: Flame Biosciences | Flamel Ireland Limited | FLAMEL IRELAND LTD

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

Last known activity

Aug 22, 2022

Acquired by Avadel Pharmaceuticals → Alkermes on Jan 1, 2017

Timeline

1990s

Jun 1, 1990
Flamel Technologies— Founded

2010s

Apr 29, 2016
ephedrine— NDA Secondary Org
Jan 1, 2017
Avadel Pharmaceuticals— Acquired By

2020s

Nov 19, 2025
Alkermes— Now

Drugs by trial phase (6 distinct, 6 trials)

Phase 3 (1 own, 0 via acquisition)

sodium oxybate

Phase 2 (5 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Recent trials (8)

NCT05395260Lead sponsorEarly Phase 1Aug 22, 2022
NCT05181865Lead sponsorPhase 1/Phase 2Jan 31, 2022
NCT05181865Study directorPhase 1/Phase 2Jan 31, 2022
NCT04983732Lead sponsorPhase 1Sep 11, 2021
NCT04758949Study directorPhase 2Aug 25, 2021
NCT04758949Lead sponsorPhase 2Aug 25, 2021
NCT02720744Lead sponsorPhase 3Nov 1, 2016
NCT01010646CollaboratorPhase 2Mar 1, 2010

Details

Founded: Vénissieux, FR Jun 1, 1990
Last known activity: Aug 22, 2022